The results of a cohort study published in JAMA Network Open revealed an epidemiologic association between postmastectomy implant-based breast reconstruction for any breast tumor and both B- and T-cell non-Hodgkin lymphomas of the breast. According to Kinslow et al, this includes diffuse large B-cell lymphoma, small lymphocytic lymphoma, and peripheral T-cell lymphoma–not otherwise specified, as well as anaplastic large-cell lymphoma.

Less than half of responding patients with cancer were previously familiar with pharmacogenomic testing and its possible benefits, according to the results of a survey conducted by the American Cancer Society Cancer Action Network (ACS CAN). Of the patients who did know about pharmacogenomic testing, only 45% learned of it through their healthcare practitioner. 

In an early-phase study reported in the Journal of Clinical Oncology, Liu et al evaluated the safety and preliminary efficacy of DEP-SN38, a polylysine-based dendrimer-nanoparticle delivery platform for the topoisomerase 1 inhibitor SN38, in patients with advanced solid tumors. SN38 is the active metabolite of irinotecan. By bypassing irinotecan’s variable hepatic conversion, DEP-SN38 aims to improve drug delivery, enhance tumor localization, and reduce gastrointestinal toxicity. 

The combination of ipilimumab and nivolumab plus radiation therapy did not lead to an improvement in progression-free survival compared with radiation therapy and temozolomide for patients with newly diagnosed MGMT-unmethylated glioblastoma, according to phase II results of the NRG-BN007 trial published in the Journal of Clinical Oncology. As a result of these primary endpoint findings, accrual for the study closed and it will not progress to a phase III study.